Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Plain-language summary

This study examines the biology of lung cancer in patients diagnosed at a young age by collecting data and specimens. It enrolls people aged 45 or younger at diagnosis who have pathologically confirmed lung carcinoma (NSCLC or SCLC). It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Dana-Farber Cancer Institute

Intervention

Data and Specimen Collection

Start date

1/1/2023

Estimated completion

8/1/2027

Countries

United States

Related genes

Locations

• Boston, United States
• Boston, United States
• Boston, United States
• Boston, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age 45 and under at lung cancer diagnosis
* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
* Provision of written informed consent
* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion Criteria:

* Individuals who decline to sign consent
* Individuals who are unable to give consent or assent and are without a designated healthcare proxy
* Compromise of patient diagnosis or staging if tissue is used for research